PTC Therapeutics (NASDAQ:PTCT) Analyst Rating Consensus

PTC Therapeutics (NASDAQ:PTCT) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2.25 by 8 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 5 Brokerage Firms have advised hold.

Other Equity analysts have also commented on the company shares. Barclays maintains its rating on PTC Therapeutics (NASDAQ:PTCT). The global brokerage major lowers the current price target from $100 per share to $40 per share. Analysts at the Barclays have a current rating of Overweight on the shares. The rating by the firm was issued on March 1, 2016.

PTC Therapeutics (NASDAQ:PTCT) stock has received a short term price target of $ 20 from 6 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $15.17. The higher estimate of target price is $40 , while the lower price target estimate is $8

PTC Therapeutics (NASDAQ:PTCT) witnessed a decline in the market cap on Tuesday as its shares dropped 3.72% or 0.26 points. After the session commenced at $7, the stock reached the higher end at $7 while it hit a low of $6.52. With the volume soaring to 1,041,065 shares, the last trade was called at $6.72. The company has a 52-week high of $62.15. The company has a market cap of $230 million and there are 34,265,019 shares in outstanding. The 52-week low of the share price is $5.27.

PTC Therapeutics, Inc. has lost 5.22% in the last five trading days and dropped 16% in the last 4 weeks. PTC Therapeutics, Inc. is up 7.87% in the last 3-month period. Year-to-Date the stock performance stands at -79.26%.

PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that target post-transcriptional control processes. The Companys internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. The Companys lead product, Translarna (ataluren), is used for the treatment of genetic disorders due to a nonsense mutation in ambulatory patients aged five years and older. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *